TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced that a ...

Natera NTRA recently announced a strategic collaboration with TransCode Therapeutics to support enrollment in a Phase 2a trial evaluating TTX-MC138 in patients with colorectal cancer (CRC). Under the ...

TransCode reports no dose-limiting toxicities, durable disease stabilization in metastatic patients; advances to Phase 2 development in ctDNA-positive cancers using next-generation RNA therapeutics.

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...

TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injection TTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive ...

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new ...

No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results Several patients in the first and second cohort remain on ...

BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and ...

TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer. The lead ...